Evidence map›Paper›PMID 34067981›Full record

ReviewInternational journal of molecular sciences2021

Pseudoephedrine-Benefits and Risks.

Krystyna Głowacka, Anna Wiela-Hojeńska

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Pseudoephedrine intoxication: sex-specific differences in clinical symptoms.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Plants (Basel, Switzerland) · 2025
    Review
  12. Observational
  13. Observational
  14. Article
  15. Article
  16. Review
  17. Article
  18. Effects of congeners of amphetamine on the human heart.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Krystyna GłowackaDepartment of Clinical Pharmacology, Wroclaw Medical University, Borowska 211a St., 50-556 Wroclaw, Poland.ORCID 0000-0002-9748-2813
Anna Wiela-HojeńskaDepartment of Clinical Pharmacology, Wroclaw Medical University, Borowska 211a St., 50-556 Wroclaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pseudoephedrine (PSE) is a drug with a long history of medical use; it is helpful in treating symptoms of the common cold and flu, sinusitis, asthma, and bronchitis. Due to its central nervous system (CNS) stimulant properties and structural similarity to amphetamine, it is also used for non-medical purposes. The substance is taken as an appetite reducer, an agent which eliminates drowsiness and fatigue, to improve concentration and as a doping agent. Due to its easier availability, it is sometimes used as a substitute for amphetamine or methamphetamine. Pseudoephedrine is also a substrate (precursor) used in the production of these drugs. Time will tell whether legal restrictions on the sale of this drug will reduce the scale of the problem associated with its misuse.

Indexed as

Bronchodilator AgentsHumansMethamphetaminePseudoephedrineRisk AssessmentSubstance-Related DisordersBronchodilator AgentsMethamphetaminePseudoephedrineadverse reactionsnon-medical usepseudoephedrinesympathomimetic

Identifiers

PMID34067981
PMCPMC8152226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.